Early relapse detection by monitoring of circulating cell-free DNA in patients with localized head and neck squamous cell carcinoma: A subgroup analysis of the multicenter randomized clinical trial IMSTAR-HN.

Hanna Jonas,Donjete Simnica,Lara Bußmann,Henrike Zech,Johannes Doescher,Simon Laban,Chia-Jung Busch,Mascha Binder

Oral oncology（2022）

引用 6|浏览12

暂无评分

摘要

•Liquid biopsy monitoring is feasible in head and neck cancer patients.•Cell-free DNA mutations after surgery identify patients at risk for early relapse.•Increasing variant allele frequencies precede clinical progression.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要